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Advanced image-guided stereotatic body lung radiotherapy techniques using 
volumetric-modulated arc radiotherapy (VMAT) with four-dimensional cone-beam 
computed tomography (4D CBCT) and CyberKnife with real-time target track-
ing have been clinically implemented by different authors. However, dosimetric 
comparisons between these techniques are lacking. In this study, 4D CT scans 
of 14 patients were used to create VMAT and CyberKnife treatment plans using 
4D dose calculations. The GTV and the organs at risk (OARs) were defined on 
the end-exhale images for CyberKnife planning and were then deformed to the 
midventilation images (MidV) for VMAT optimization. Direct 4D Monte Carlo 
dose optimizations were performed for CyberKnife (4DCK). Four-dimensional dose 
calculations were also applied to VMAT plans to generate the 4D dose distributions 
(4DVMAT) on the exhale images for direct comparisons with the 4DCK plans. 4DCK 
and 4DVMAT showed comparable target conformity (1.31 ± 0.13 vs. 1.39 ± 0.24, p = 
0.05). GTV mean doses were significantly higher with 4DCK. Statistical differences 
of dose volume metrics were not observed in the majority of OARs studied, except 
for esophagus, with 4DVMAT yielding marginally higher D1% than 4DCK. The normal 
tissue volumes receiving 80%, 50%, and 30% of the prescription dose (V80%, V50%, 
and V30%) were higher with 4DVMAT, whereas 4DCK yielded slightly higher V10% 
in posterior lesions than 4DVMAT. VMAT resulted in much less monitor units and 
therefore greater delivery efficiency than CyberKnife. In general, it was possible 
to produce dosimetrically acceptable plans with both techniques. The selection of 
treatment modality should consider the dosimetric results as well as the patient’s 
tolerance of the treatment process specific to the SBRT technique. 
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I. IntroDuCtIon
Stereotactic body radiotherapy (SBRT) is an accepted treatment alternative to surgery for medi-
cally inoperable non-small cell lung carcinoma (NSCLC). Promising results of phase I/II trials 
in early-stage I peripherally located lung tumors have led to other studies and clinical trials of 
locally advanced stage III/IV NSCLC.(1,2)
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The delivery technique of SBRT spans a broad spectrum. Using four-dimensional (4D) dose 
calculations, Wu et al.(3) suggested that treatment planning with population-based margins on the 
free breathing CT resulted in similar mean tumor dose but increased mean lung dose, compared 
to the individualized internal target volume (ITV) approach, and beam gating at end-inhale 
or end-exhale. For free-breathing SBRT, an alternative approach to the ITV is the concept of 
mean target position (MidP). The advantages of planning and delivering the treatment plans at 
the time-weighted average tumor position were discussed by several authors.(4,5) For example, 
Guckenberger et al.(5) estimated that 2.4 and 6.0 mm margins around the clinical target volume 
(CTV) at the approximate time-weighted average position were needed to compensate for motion 
amplitudes of 10 and 20 mm. This is roughly one-third of the internal margin. Sonke et al.(6) 
were among the first to demonstrate the clinical feasibility of using the 4D cone-beam computed 
tomography (4D CBCT) to register the soft-tissue tumor at its time-weighted average position 
for treatment verification. Real-time tumor tracking with CyberKnife is another promising 
technique to deliver free-breathing SBRT. This system tracks the implanted surrogates or the 
soft-tissue tumor based on a sophisticated feedback loop that measures the respiration signal 
and the position of the internal fiducial markers/soft tissue tumor and adjusts the treatment 
beam alignment according to the predicted target position.(7,8) This advanced motion manage-
ment technique enables significant reduction of the planning target volume (PTV) margin and 
potentially better sparing of the normal tissue doses.
Despite the recent development of different advanced radiotherapy delivery strategies, there 
are limited data quantifying their relative benefits for lung cancers. Many studies have compared 
the dosimetric advantages of noncoplanar 3D CRT, intensity-modulated radiotherapy (IMRT) 
and volumetric-modulated arc radiotherapy (VMAT).(9-12) To our knowledge, there were only a 
limited number of dosimetric studies comparing ITV-based 3D CRT/dynamic conformal arc in 
conventional linac with real-time tumor tracking using CyberKnife, mainly on the static patient 
geometry.(13-15) In the lack of further evaluations of the relative advantages of the CyberKnife 
using target tracking and the VMAT using online 4D CBCT setup verification, we aimed to 
perform a planning evaluation of these strategies to identify the patient groups that would 
benefit from the use of one treatment technique or the other.
 
II. MAtErIALS AnD MEtHoDS
A.  Patient data and 4D-Ct imaging
Four-dimensional computed tomography (4D CT) images of 14 primary non-small cell lung 
carcinomas were used to create VMAT plans at the midventilation phase for gantry-based 
treatment delivery, and IMRT plans at the end-exhale phase for CyberKnife. These patients 
had been treated with either 60 Gy in 3 fractions (n = 12) or 48 Gy in 6 fractions (n = 2), based 
on a risk adapted strategy as described by van der Voort van Zyp et al.(16) Tumor characteris-
tics were listed in Table 1. Tumors were considered anteriorly located if the location of their 
center-of-mass were in the area of the anterior half of the ipsilateral lung in the transverse plane. 
Similar definition applied to posterior tumors. The image thickness was 2.5 mm. Each 4D CT 
dataset consisted of ten equally time-binned 3D CT series. All 3D CT series were transferred 
to MultiPlan treatment planning system (TPS) version 4.0.x (Accuray Inc., Sunnyvale, CA) 
and Pinnacle3 TPS v.9.0 (Philips Medical Systems, Eindhoven, The Netherlands).  
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B.  4D treatment planning of CyberKnife
For CyberKnife treatment planning, the organ structures were contoured at the end-exhale 
in the MultiPlan TPS (4.0.x). A uniform 5 mm safety margin was added to the gross tumor 
volume (GTVCK) to produce the planning target volume (PTVCK), as suggested by Lu et al.
(17) 
The primary planning objective was to achieve at least 95% PTV coverage of 100% of the 
prescription dose. The treatment doses were prescribed to the 62%–83% isodose lines (maxi-
mum dose = 100%). For critical organs, the dose-volume limits were listed in Table 2. They 
were set based on the clinical outcomes reported by van der Voort van Zyp et al.(16,18) Note 
that 0.5 cc of selected organs were allowed to get 5% higher dose than the set constraints for 
the treatment group of 48 Gy/6 fractions. 
All treatment plans were created using the built-in 4D optimization module in the MultiPlan 
TPS. The 4D optimization is similar to standard three-dimensional (3D) optimization. It began 
by a search of a set of candidate beams with optimized weights that best satisfied the user-
specified clinical objectives (e.g., maximize tumor minimum dose, maximize target conformity, 
and minimize maximum dose of normal organs). It substituted the 3D dose matrix in standard 
3D optimization with 4D dose matrices corresponding to independent dose distributions at dif-
ferent breathing states. It further employed B-spline deformable vector fields that describe the 
trajectory of each anatomic voxel during respiratory cycle to accumulate doses calculated in 
different breathing states with equal weight onto a common reference space on which structure 
contours were defined and evaluated. Beam weights were varied so that the accumulated 4D 
dose distribution approached the planning objectives. Ideally, the explicit inclusion of organ 
motion and deformation during the inverse optimization process should ensure 95% PTV 
coverage of the prescription dose over the breathing cycle. Note that the variations of organ 
motion pattern and deformation between the treatment fractions were assumed to be negligible, 
as demonstrated in the previous studies.(19,20)  
Since lung consists of a large amount of heterogeneities of low-density lung tissues, Monte 
Carlo (MC) dose calculation(21) was applied during the 4D optimizations, as well as in the final 
Table 1. Tumor characteristics. 
      Treatment 3D
   GTV PTVCK PTVVMAT Dose
a Motion
 Patient # Tumor Location (cc) (cc) (cc) (Gy) (mm)
 1 RUL; attached to anterior  1.2 6.1 11.2 60  7.6
  chest wall 
 2 RUL; anteriorly located 73.8 118.7 188.1 60 22.8
 3 RUL; anteriorly located  7.5 20.3 34.8 60 4.6
 4 RML; anteriorly located 2.5 9.2 16.7 60 8.5
 5 RUL; anteriorly located  31.7 63.1 88.1 60 2.1
 6 RML; anteriorly located 7.8 22.7 40.8 60 4.6
 7 RML; anteriorly located 3.7 12.7 21.0 60 3.7
 8 RLL; posteriorly located 0.6 4.2 8.2 60 6.0
 9 RLL; posteriorly located 4.2 16.7 27.5 60 9.2
 10 LLL; posteriorly located; proximal  77.9 109.0 130.7 48 4.0
  to esophagus, aorta, and cord  
 11 RLL; posteriorly located 13.0 31.5 46.9 60 3.6
 12 LUL; attached to posterior chest wall  15.4 33.4 60.2 48 11.0
  and close to esophagus and aorta 
 13 RUL; posteriorly located  8.1 23.1 32.8 60 7.2
 14 RLL; attached to posterior chest wall 10.2 27.8 53.3 60 20.0
a Prescription doses were 60 Gy/3 fractions for peripheral lesions or 48 Gy/6 fractions for central lesions.
PTVCK = planning target volume of CyberKnife plan; PTVVMAT = planning target volume of 4D VMAT plan. 
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dose calculations, forming a direct 4D Monte Carlo optimization framework to ensure proper 
dose coverage of the PTV and accurate estimates of the doses in the organs at risk (OARs). 
The sequential algorithm was used for all plan optimizations. The sequential algorithm was 
executed sequentially as a series of individual optimization steps. Each step performed a linear 
programming optimization applied to a single objective cost function that was designed to 
correspond to a specific clinical objective (e.g., target dose coverage, target dose conformity, 
minimum dose to target, and maximum / mean dose to critical organs). The initial number of 
beams available to the optimization solution was determined by the number of predefined cir-
cular cones. There was no limit to the total number of monitor units (MU) for all plans. But to 
reduce the overall treatment time, the beam reduction technique was performed to remove from 
the optimization process those beams whose MU/fraction was below 40 (i.e., corresponding 
to an average breathing cycle of 4 seconds at fixed dose rate of 600 MU/min) and reoptimized 
using only the remaining beams. The number of beams of the resulting treatment plans ranged 
from 100–150 (mean = 120 beams). In addition, the MU/node (i.e., the position of the robot 
along a certain irradiation path) of each fraction was limited to no more than 200. The final 4D 
MC optimized dose distribution of the CyberKnife plan was called 4DCK dose. To make the 
MC dose calculation time reasonable, the relative statistical uncertainty was set to 4% during 
optimizations and reduced to 1% in all final dose calculations. The final dose resolution grid 
was approximately 1.1 × 1.1 × 2.5 mm3. 
C.  4D treatment planning of VMAt
As mentioned previously, VMAT planning was performed on the MidV images. The midven-
tilation phase was determined by propagating the GTVCK from the reference exhale phase to 
other phases in transitive manner by means of constrained intensity-based deformable image 
registrations (DIR) that were performed with MiM Maestro v.5.0 (MIM Software Inc., Cleveland, 
OH). Subsequently, the 3D CT frame in the 4D CT dataset that best approximates the mean 
target position in the craniocaudal direction was used for VMAT treatment planning, aiming to 
remove the systematic error from respiratory motion. It is worth noting that choosing a phase 
image that is not the perfect time percentage corresponding to the MidP induces a generally 
small baseline shift. However, this discrepancy could be effectively corrected by real-time 
tumor tracking and 4D CBCT. In addition, the error of baseline shifts induced by physiologi-
cal sources generally exceeds the imaging-induced baseline shift. Nonetheless, minimizing 
this imaging-induced shift helps to minimize discrepancies between the positions of surround 
tissues during treatment delivery.
The GTV-to-PTV margin was calculated for each patient according to the van Herk’s non-
linear margin formula.(4) The final margin ranged from 6.5 to 9.7 mm in the superior–inferior 
(SI) direction, 6.2 to 7.4 mm in the anterior–posterior direction (AP), and 6.1 to 7.4 mm in 
the left–right (LR) direction for the motion amplitude between 1.0 and 22.5 mm (SI), 0.1 and 
3.5 mm (AP), and 0.2 to 3.8 mm (LR), respectively. 
Table 2. Summary of critical organ dose constraints. 
   Schedule Schedule 
   3 × 20 Gy 6 × 8 Gy 
   Dose per fraction Dose per fraction
 Organ Volume (Gy) (Gy)
 Spinal cord  Any point 8 4.5
 Esophagus Any point 7 6
 Heart  Any point 12 8
 Trachea and main bronchus Any point 10 8
 Lung V20 (NTD2) <31% <31%
V20 = percentage of volume receiving at least 20 Gy normalized to 2 Gy fractions; NTD2 = normalized total dose in 
2 Gy fractions assuming the α/β ratio = 3 Gy. 
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The SmartArc module in Pinnacle3, version 9.0 (Philips Medical Systems, Eindhoven, The 
Netherlands) was used to create the VMAT plans. Details of the SmartArc algorithm has been 
described by Bzdusek et al.(22) Briefly, the VMAT optimization began with the generation of 
coarse segments around the user-defined arc. This was followed by an intensity modulation 
optimization on the fluence maps for these segments. The fluence maps were converted to 
multileaf collimator (MLC) segments, two per angle, and were subsequently filtered and evenly 
distributed around the arc. Interpolated segments were then added to reach a final fine arc spac-
ing which was set to 4° for all optimized plans. The resulting segments were optimized using 
direct machine parameter optimization (DMPO) to satisfy the planning objectives and other 
machine-specific constraints such as leaf motion, dose rate, and gantry speed.(22)        
In our study, VMAT plans consisting of one to three full and/or partial arcs were produced for 
an Elekta Beam Modulator 6 MV linear accelerator (Elekta Oncology Systems Ltd., Crawley, 
UK) that was equipped with 4 mm MLC and operated at a maximum dose rate of 400 MU/
min. The physical constraints of VMAT planning included a minimum segment area of 4 cm2, 
a minimum segment MU of 20, a 10 iteration segment weight reoptimization to enhance target 
coverage, and maximum leaf speed of 0.4 cm/gantry degree. The planning objectives were the 
same to those applied in the CyberKnife planning. The treatment doses were prescribed to the 
78%–85% isodose lines. The collapsed cone convolution–superposition algorithm (CCCS) with 
heterogeneity correction was employed in all final dose calculations at a resolution of 2.5 × 
2.5 × 2.5 mm3. For each patient, the optimal VMAT plan (3DVMAT) was applied to recalculate 
the dose distributions on other 3D CT images in the 4D CT dataset using the same monitor 
units and the same MLC segments. These individual dose matrices were then warped to the 
end-exhale phase by applying the deformation vectors from deformable image registrations 
on the MiM Maestro workstation. Since the 4D dose distributions of CyberKnife (4DCK) and 
VMAT (4DVMAT) plans were both accumulated to the same breathing phase at end-exhalation, 
direct dosimetric comparisons of these dose distributions were feasible using the same set of 
DICOM RT structure.  
D.  Dosimetric evaluations
The 4D dose distributions of CyberKnife and VMAT plans were evaluated by different dosi-
metric parameters obtained from the dose-volume histograms (DVHs). First, the conformity 
of prescription dose to the PTVCK and the PTVVMAT was quantified with the new conformity 
index (nCI), defined as:(23) 
   
 (PI PTV)/TVIP2 (1)
where PI is the volume covered by the prescription isodose line, and TVIP is the volume of the 
PTV covered the prescription isodose line. A larger nCI value indicates less conformity and 
vice versa. The homogeneity index was excluded from the dosimetric evaluations since dose 
heterogeneity inside the target volume is generally not a concern in SBRT and even desired. Other 
evaluation metrics included the mean dose of GTV, the near-minimum dose of GTV (i.e., dose 
to 99% of GTV volume (D99%)), the percentage volume of PTV, and organs receiving at least 
X Gy, Vx , where X equals 60 or 48 Gy for the evaluation of PTV dose coverage (V60Gy/48Gy) 
and 20 Gy for the evaluation of the risk of lung toxicity (i.e., V20Gy), and varies from 80%, 50%, 
30%, and 10% of the prescribed doses 60 Gy or 48 Gy (i.e., V80%, V50%, V30%, and V10%) for 
quantifying the high to low doses in the normal tissue. The near-maximum dose (i.e., dose to 
1% organ volume (D1%)) of the spinal cord, esophagus, and trachea were also compared.   
The efficiency of treatment delivery was evaluated by comparing the per-fraction number 
of monitor units (MU) and the per-fraction beam-on time. The beam-on time for CyberKnife 
treatment was estimated by the ratio of per-fraction monitor units to the dose rate (600 MUs/
minute), while it was taken as the estimate from the Pinnacle TPS. 
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E.  Statistical analysis
Statistical comparisons between CyberKnife and VMAT treatment plans were based on the 
two-sided Wilcoxon match-paired signed rank tests and correlations between variables were 
performed with Spearman’s rank correlation. Differences were considered significant when 
p < 0.05. All statistical analyses were performed with the MATLAB statistical toolbox (The 
MathWorks, Inc., Nantick, MA).   
 
III. rESuLtS 
A.  tumor dose and target conformity
Dose-volume indices of the GTV and the PTV for the 4DCK and 4DVMAT plans, and the original 
3D VMAT (3DVMAT) plans were summarized in Table 3. On average, the organ motion reduced 
the PTV V60Gy/48Gy by 8.9%, and the GTV D99% by 2.7%, but hardly changed the GTV mean 
dose (< 0.3%) with and without 4D dose calculations for VMAT plans. By contrast, CyberKnife 
treatments combining target tracking with 4D inverse planning ensured adequate PTV cover-
age (95.2% ± 1.7%) comparing to the 4DVMAT plans (86.1% ± 8.7%). The GTV mean dose 
was higher for the 4DCK plans than the 4DVMAT plans by 12.0% in the 60 Gy group and 8.6% 
in the 48 Gy group, respectively. 
Table 3. Summary of the dosimetric results for CyberKnife and VMAT plans over the 14 patients. 
  4DCK 4DVMAT 3DVMAT p–value
 nCI
 Mean ±1 SD 1.31±0.13 1.39 ± 0.24 1.23±0.18  p>0.05a
 Range 1.17–1.64 1.10–1.93 1.06–1.74  p = 0.05b
 GTV Mean Dose Relative To
 The Prescription Dose (%)    
 Mean±1 SD 133.2±9.5 119.0 ± 4.2 119.4±4.4  p<0.001a
 Range 112.7–145.8 109.6–127.0 109.8–127.8  p<0.001b
 GTV D99% Relative To
 The Prescription Dose (%)    
 Mean ± 1 SD 113.2±9.5 110.3±6.8 113.3±5.4  p>0.05a
 Range 92.7–128.2 96.2–119.3 101.46–20.2  p>0.05b
 V60Gy / 48Gy (%)
 Mean ± 1 SD 95.2±1.7 86.1±8.7 95.0±0.0  p = 0.001a
 Range 90.4–97.6 68.4–94.1 94.9–95.1  p>0.05b
 Lung V20Gy (%)    
 Mean ± 1 SD 6.2±3.7 6.6±3.2 6.3±2.9  p>0.05a
 Range 1.1–14.0 2.5–14.8 2.4–12.7  p>0.05b
 Cord D1% (Gy)    
 Mean ± 1 SD 10.8±7.3 11.7±7.7 12.0±7.8  p>0.05a
 Range 4.3–27.0 2.2–30.7 2.2–30.8  p>0.05b
 Esophagus D1% (Gy)    
 Mean ± 1 SD 9.7±7.1 14.7±11.7 14.8±11.7  p = 0.05a
 Range 0.9–24.0 4.7–53.2 4.4–53.1  p = 0.05b
 Trachea D1% (Gy)    
 Mean ± 1 SD 9.6±9.9 10.7±10.2 10.5±10.3  p>0.05a
 Range 0.7–33.2 0.2–25.4 0.2–24.5  p>0.05b
a 4DCK vs. 4DVMATb 4DCK vs. 3DVMAT
SD = standard deviation; 4DCK and 4DVMAT = 4D dose distributions of CyberKnife and VMAT plans at end-exhale 
phase; 3DVMAT = original 3D VMAT dose distributions at midventilation; nCI = new conformity index; V20Gy = lung 
volume receiving xx> 20 Gy; Dx% = dose to X% of organ of interest. 
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The target conformity nCI ranged from 1.17 to 1.64 for the 4DCK plans, and from 1.07 to 1.74 
for the 4DVMAT plans. The organ motion caused observable degradation of the PTV conformity 
in the 3DVMAT plans. The mean nCI increased from 1.23 in the original 3DVMAT plans to 1.39 in 
the 4DVMAT plans. The target conformity of the 3DVMAT plans was superior to the 4DCK plans in 
six out of seven posterior lesions and in five out of seven anterior lesions (p = 0.05), as shown 
in Fig. 1. The target conformity of the 4DVMAT plans was superior to the 4DCK plans in only 
two out of seven posterior lesions and in three out of seven anterior lesions (p > 0.05). 
B.  Doses of organs at risk 
For OARs, the DVH analysis of the 4DCK, 4DVMAT, and 3DVMAT plans were also given in 
Table 3. Except for the marginal significance of the difference in D1% of the esophagus, the 
dosimetric indices of other OARs were statistically equivalent between 4DCK and 4DVMAT. For 
normal lung, V20Gy of 4DCK and 4DVMAT differed by less than 1% in both 60 Gy group and 
48 Gy group. There was notable difference between the 4DCK and the 4DVMAT dose distribu-
tions in one patient (patient no. 10) whose GTV was in close proximity to the esophagus and 
the cord (Fig. 2). For this patient, the 4DVMAT plan using one full arc (180°–179.9°) and one 
partial arc (300°–179.9°) has not been able to meet the planning objectives for the spinal cord 
and the esophagus, while the 4DCK plan managed to reduce the D1% of the spinal cord and 
the esophagus by 40% (21.5 Gy vs. 30.1 Gy) and 117% (24.5 Gy vs. 53.2 Gy), respectively, 
mainly due to the smaller PTV. 
Fig. 1. The new conformity index (nCI) are shown for the 4D optimized CyberKnife plans and the 4D accumulated 
VMAT plans on the exhale images, and the 3D VMAT plans on the midventilation images. The shaded area corresponds 
to posterior lesions.
 
FIG. 1 The new conformity index (nCI) were shown for the 4D optimized CyberKnife plans and 
the 4D accumulated VMAT plans on the exhale images, and the 3D VMAT plans on the mid-ventilation 
images. The shaded area corresponds to posterior lesions.  
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C.  Integral dose and treatment efficiency 
Comparisons of the high- to the low-dose volumes receiving 80%, 50%, 30%, and 10% of the 
prescription dose (e.g., V80%, V50%, V30%, and V10%) were shown for each patient in Fig. 3. 
The 4DCK plans significantly reduced the normal tissue from the high- to the medium-dose 
regions (V80% = 69 ± 58 cc and 93 ± 81 cc, V50% = 156 ± 122 cc and 226 ± 194 cc, and V30% = 
413 ± 348 cc and 522 ± 379 cc in 4DCK and 4DVMAT plans, respectively; all p-values < 0.05), 
and yielded comparable low-dose volumes V10% (1793 ± 1141 cc vs. 1618 ± 742 cc; p > 
0.05). Figure 3 also suggested that the difference of V10% differed by the tumor location, with 
CyberKnife producing larger V10% than VMAT in posterior lesions and vice versa. The differ-
ences (4DCK - 4DVMAT) of V80%, V50%, V30%, and V10% were plotted as a function of tumor 3D 
motion range in Fig. 4. The Spearman’s rank correlation coefficients between the 3D motion 
and the Vx% indices were -0.58, -0.59, -0.59, and 0.13, respectively. All the coefficients were 
statistically significant, except for V10%.
The monitor units per fraction and the estimated delivery time were reported for each patient 
in Table 4. The number of MUs/Gy/fraction ranged from 167 to 357 and from 46 to 68 for 
CyberKnife treatments and VMAT treatments, respectively. The beam-on time/fraction ranged 
from 16.7 to 22.3 minutes for CyberKnife treatments and from 8.3 to 10.8 minutes for VMAT 
treatments, respectively.  
 
Fig. 2. 4D dose distributions of the CyberKnife plan (a) and (b), and the VMAT plan (c) and (d)). Dose-volume histograms 
(DVHs) of the 4D CyberKnife and the 4D VMAT plans are shown (e) for selected organs. Note the dose levels in ((a)–(d)) 
roughly correspond to 80%, 50%, 30%, 10%, and 5% of the prescription dose of 48 Gy.
 
FIG. 2 4D dose distributions of the CyberKnife plan (A and B) and the VMAT plan (C and D). 
Dose-volume histograms (DVHs) of the 4D CyberKnife and the 4D VMAT plans are shown in (E) for 
selected organs. Note the dose levels in (A!D) roughly correspond to 80%, 50%, 30%, 10%, and 5%
of the prescription dose of 48 Gy.     
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FIG. 3 Normal tissue volume receiving 80% (V80%), 50% (V50%), 30% (V30%) and 10% (V10%) of 
the prescription dose for the 4D optimized CyberKnife (4DCK) dose distributions (black) and the 4D 
accumulated VMAT (4DVMAT) dose distributions (grey). The shaded areas correspond to posterior 
lesions.    
Fig. 3. Normal tissue volume receiving 80% (V80%) (a), 50% (V50%) (b), 30% (V30%) (c), and 10% (V10%) (d) of the 
prescription dose for the 4D optimized CyberKnife (4DCK) dose distributions (black) and the 4D accumulated VMAT 
(4DVMAT) dose distributions (grey). The shaded areas correspond to posterior lesions.  
Fig. 4. Differences of normal tissue volume receiving at least 80%, 50%, 30%, and 10% of the prescription dose (V80%, 
V50%, V30%, and V10%) between the 4D CyberKnife and the 4D VMAT plans (4DCK-4DVMAT) as a function of superior–
inferior tumor motion range. Linear regressions lines (red solid lines) were also plotted.
!
FIG. 4 Diffe ences of norm l tissue volume receiving at least 80%, 50%, 30% and 10% of the 
prescription dose (V80% ,V50% ,V30% and V10%) between the 4D CyberKnife and the 4D VMAT plans 
(4Dck ! 4DVMAT) as a function of superior-inferior tumor motion range. Linear regressions lines (red 
solid lines) were also plotted. 
!
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IV. DISCuSSIon
A dosimetric comparison between CyberKnife treatments delivered under the image-guided 
real-time target tracking and VMAT treatments delivered based on the online 4D CBCT setup 
has been performed using a 4D dose calculation framework to explicitly include the effects 
of intrafractional organ motion. This study demonstrated that considering VMAT delivery 
without accounting for the effects of organ motion could lead to biased results that would 
favor VMAT plans over CyberKnife plans in terms of better target conformity. In a recent 
study, Atalar et al.(15) evaluated the conformity of linac-based fixed-field 3D conformal radio-
therapy (3D CRT) and dynamic conformal arc radiotherapy vs. CyberKnife. Without 4D dose 
calculation, Atalar et al. suggested linac-based SBRT was associated with superior conformity 
to CyberKnife. In contrast, Ding et al.(14) showed inferior conformity index (CI) with the 4D 
accumulated dose distributions of the 3D CRT plans compared to the 3D dose distributions of 
CyberKnife (1.64 ± 0.29 vs. 1.16 ± 0.06), partly resulting from the inconsistent definition of 
the PTV (ITV + 5 mm for treatment planning vs. GTV + 5 mm in calculating the CI). Overall, 
the organ motion smeared out the dose distributions, causing degraded target conformity and 
reduced PTV coverage in the VMAT plans designed on the MidV images, although it hardly 
affected the minimum (D99%) and mean dose of GTV. Using consistent definition of the GTV 
and the PTV (on exhale phase) for comparisons, we showed that the PTV conformity of the 
4D optimized CyberKnife plans was inferior to the 3D VMAT plans, but was comparable to 
the 4D VMAT plans. This suggests the importance of including the organ motion effects when 
comparing different treatment strategies. Overall, the CyberKnife plans produced higher GTV 
mean doses than VMAT plans (Table 1). It is expected that the higher GTV mean doses will 
not lead to notable differences in clinical outcomes, as several studies have suggested that the 
local tumor control became saturated beyond biological effective dose (BED) of 100 Gy10. The 
characteristics of the different delivery techniques by VMAT and CyberKnife led to observable 
differences in the low-dose volume (V10%) between anterior and posterior lesions, as shown 
in Fig. 3. The limitation of robotic-armed linac to irradiate from under the couch attributed 
to larger difference of V10% between 4DCK and 4DVMAT dose distributions in posterior lesions 
than in anterior lesions (mean = 374 cc. vs. -22.4 cc.). A common characteristic of the 4DVMAT 
plans the greater dose contributions from posterior side, whereas the 4DCK plans had more 
contributions from the superior and inferior sides. For most anterior lesions, the 4DVMAT plans 
Table 4. Summary of the treatment monitor units and the beam-on time of the CyberKnife and the VMAT plans.
 Monitor Units/Gy/Fraction Beam-On Time/Fraction (minutes)
 Patient No. CyberKnife VMAT CyberKnife VMAT
 1 167 68 16.7 11.2
 2 259 58 25.9 11.5
 3 172 65 17.2 14.3
 4 236 61 23.6 10.9
 5 204 60 20.4 12.5
 6 205 46 20.5 8.5
 7 200 53 20.0 10.8
 8 195 46 19.5 8.3
 9 357 54 35.7 10.7
 10 193 82 15.5 14.3
 11 287 55 28.7 9.9
 12 271 88 21.7 13.3
 13 190 57 19.0 10.7
 14 199 54 19.9 9.9
 mean ± 1 SD (20 Gy × 3) 223±55 56±7 22.3±5.5 10.8±1.6
 mean (8 Gy × 6) 232 85 18.6 13.8
 p-value  p<0.05 p<0.05
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resulted in higher dose around the gantry rotation path compared to the 4DCK plans whereas, 
for posterior lesions, the 4DCK plans were mostly associated with higher doses anterior to the 
lesions due to the missing irradiation coming from underneath the patient.      
This study used one to three full and/or partial arcs in VMAT planning. It is important 
to note that the quality of VMAT plan is influenced by the treatment planning system (e.g., 
RapidArc of Eclipse (Varian Medical Systems, Palo Alto, CA) or SmartArc of Pinnacle) and 
other factors such as how many arcs are used, and whether coplanar or noncoplanar arcs are 
used. For example, potential improvement of combining VMAT with static beams has been 
suggested by Chan et al.,(24) but such hybrid VMAT planning option is not supported in the 
current version of Pinnacle TPS. In another recent planning study, Merrow et al.(12) compared 
3D CRT with VMAT using multiple coplanar and/or noncoplanar arcs. Merrow et al. strongly 
recommended the use of multiple (partial) arcs to achieve good target conformity and reduction 
of critical organ doses in lung SBRT. Nonetheless, there were other studies showing that one 
partial arc can do just as well to meet the dose constraints as multiple arcs in lung SBRT.(9,11) 
In this study, we found that one partial or full arc was sufficient for most cases, but it generally 
required more arcs for the complex cases where GTVs were surrounded by multiple critical 
organs (patients no. 10 and 12). This is consistent with the early findings of Guckenberger et 
al.(20) who evaluated the need of more than one single arc for complex-shaped target volumes. 
Using the same SmartArc technique as in the present work, they suggested that for simple target 
shape (prostate), single-arc VMAT is sufficient while for complex target shape, multiple-arc 
VMAT improved dosimetric results compared to the single-arc VMAT at the cost of increased 
delivery time, increased MUs, and increased spread of low doses. Furthermore, noncoplanar 
arc may improve the dose distribution, but it also brings practical problem with respect to setup 
verification using on-board 3D/4D CBCT. 
Compared with SBRT based on the conventional ITV approach, VMAT treatment using the 
MidV concept could facilitate significant margin reduction.(4) Over all patients, the PTVVMAT 
size was larger than the corresponding PTVCK by 18.7 cm
3 because larger margin was needed 
to compensate for the intra- and interfractional variability of organ motion, tumor baseline, and 
setup. The larger PTVVMAT did not caused significantly higher D1% of the spinal cord, esophagus, 
and trachea or V20Gy of lung in most cases, except for one patient (patient no. 10). For this patient, 
4D VMAT using one full and one partial arc yielded esophagus D1% of 53.2 Gy/6 fractions, 
which was definitely unsuitable to undergo SBRT. For the same patient, CyberKnife reduced the 
esophagus D1% to 24.5 Gy. The other most notable dosimetric effect of larger PTVVMAT was the 
increased normal tissue volume receiving high to medium doses (Fig. 3). A preliminary plan-
ning study by Chin et al.(25) has argued that gated SBRT VMAT reduced volumes of irradiated 
lung volume and some critical organs by irradiating the tumor when it falls into a certain time 
or amplitude window. However, it is well known that gated beam delivery based on external 
surrogate is subject to serious uncertainty of the correlation between the internal organ and the 
external surrogate that is crucial to the geometric accuracy of tumor targeting.(26-28) Korreman 
et al.(29) also argued that the gating technique does not facilitate margin reduction if there is no 
image-guidance technique to ensure tumor at the gated position. 
A major advantage of VMAT treatment was the smaller number of MUs and hence much 
shorter beam-on time. On average, the VMAT plans consumed 163 MUs/Gy less than the 
CyberKnife plans did because the beam aperture was opened for most of the VMAT subseg-
ments, whereas CyberKnife made use of small collimated beams to dose paint the target, thus 
wasting a large amount of MUs. If the VMAT treatments were delivered in the flattening filter-
free mode, the treatment time could be reduced further, down by 20%–350% compared to the 
conventional VMAT delivery with flattening filter,(30,31) and thereby decreasing the patient’s 
discomfort and the intrafractional uncertainties. Another downside of CyberKnife is the need 
of fiducial markers as the tumor surrogate. There were two major problems with fiducial mark-
ers: migration and pneumothorax due to the implant process.(32) Most recently, Bibault et al.(8) 
reported the first clinical outcomes of fiducial free robotic SBRT using the CyberKnife Xsight 
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Lung Tracking System (XLTS). However, XLTS is suitable to a subset of tumors of certain 
sizes in certain locations. By contrast, 4D CBCT correction protocol has the advantage of direct 
detection of the soft-tissue tumor located anywhere in the thorax.  
It is important to note that significant uncertainty of our results may result from the use of 
different deformable image registration algorithms to interpolate the VMAT and the CyberKnife 
doses on different breathing geometries to the reference end-exhale frame for dosimetric 
comparisons. Despite the similarity of these deformable registration algorithms (both are 
intensity-based and employ free form deformation), the results of a multiinstitutional study 
comparing different deformable registration models has demonstrated that differences of the 
similarity measure, the regularization term, and the optimization method still contributed to 
uncertainty of the resulting deformation fields.(33) Furthermore, the deformation image registra-
tions applied in this study were based on a simple voxel warping approach without congruent 
energy and mass mapping.(34) On the other hand, the 4D dose distribution is frequently obtained 
by deforming the dose calculated on different breathing geometries with equal weight onto a 
reference geometry. This general approach ignores the dynamic interaction between the MLC’s 
movement and organ movement, or the so-called interplay effect. Recently, Werner et al.(35) 
and Rao et al.(36) have separately studied the interplay effect using a plan- and patient-specific 
beam weight approach for conventionally fractionated step-and-shoot IMRT and convention-
ally fractionated and hypofractionated VMAT. Both groups concluded negligible differences 
between the general equal-weight 4D dose calculation approach with the one that specifically 
considered the relationship between the movements of the MLC and the target. Therefore, one 
can assume that ignoring the interplay effect does not significantly change our results of the 
4D VMAT dose calculations. 
Another limitation of the present work and many other dosimetric evaluations was the use 
of different dose calculation algorithms. Evaluations of dosimetric metrics obtained from dif-
ferent dose calculation algorithms (CCCS for VMAT plans and MC for CyberKnife plans) may 
subject our results to systematic biases. However, the dose differences between Monte Carlo 
and collapsed cone convolution–superposition algorithms are generally much smaller than 
between convolution–superposition and pencil-beam algorithms.(37) Therefore, results of this 
study can still be considered more reliable than other previous studies that based their dosimetric 
comparisons on simple pencil-beam or convolution–superposition algorithms.(13-15)
Several groups have recently developed different frameworks of direct 4D VMAT opti-
mization and have shown promising results.(38,39) Nonetheless, 4D dose calculation is not 
a standard option in the majority of commercial TPS. In general clinical setting, this means 
that the deformable image registration and dose calculation have to be done separately using 
different tools (e.g., the Pinnacle TPS for dose calculations and MiM Maestro workstation 
for deformable dose accumulation, as in our case) which requires tremendous manpower and 
resources. For this study, treatment planning with Pinnacle 810 workstation (2.8 GHz AMD 
Opteron) and subsequent 4D dose calculation for VMAT plans required at least 3.5 working 
days (8 hours per working day). For CyberKnife, the built-in 4D optimization system slightly 
eased the treatment planning process, but still required at least two working days to obtain a 
reasonable plan using our planning strategy (higher statistical uncertainty 4% during optimiza-
tion and 1% in final dose calculation) on the current system (Intel Xeon Processor 3.00 GHz). 
Whether 4D dose calculation is needed to include the dosimetric effect of organ motion and 
dynamic beam movement is still controversial. The clinical significance of this dose calculation 
method should be decided on a patient-by-patient basis. Other simplified approaches, such as 
using the averaged density CT images for dose calculation, should be considered to streamline 
the treatment planning procedure.    
 
148  Chan et al.: Comparing 4D CyberKnife and VMAt for lung SBrt 148
Journal of Applied Clinical Medical Physics, Vol. 14, no. 4, 2013
V. ConCLuSIonS
Both CyberKnife using real-time tracking and VMAT using online 4D CBCT treatment setup 
are deemed excellent for lung SBRT as 4D distributions showed comparable target conformity, 
adequate tumor dose, and dosimetrically acceptable dose-volume metrics of different critical 
structures. CyberKnife using image-guided real-time tracking may have some advantage over 
free-breathing VMAT in the treatment of tumors that show large motion range and/or are sur-
rounded by multiple critical organs, such as those in the central zone, mainly because it can 
allow smaller safety margin and hence smaller irradiated normal tissue volumes. For peripheral 
lesions with relatively small motion, the much shorter duration of the VMAT treatment may 
benefit some patients who have suboptimal physical conditions and cannot tolerate the long 
duration of the CyberKnife treatment.   
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